Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
11.41
+0.96 (+9.19%)
Official Closing Price
Updated: 8:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Cybin to Participate at the 2023 Milken Institute Future of Health Summit
November 03, 2023
From
Cybin Inc.
Via
Business Wire
Single Dose Of Cybin's Psilocybin Shows Compelling Patient Outcomes, Phase 2 Results Find
November 01, 2023
Psychedelics company Cybin Inc. (NYSE: CYBN) shared its Phase 2 study interim results for its psilocybin analog CYB003
Via
Benzinga
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Releases Update, Notes Upcoming Pipeline Milestones
November 01, 2023
Via
Investor Brand Network
Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
November 01, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
October 31, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
October 29, 2023
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents
October 26, 2023
Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.)
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Portfolio to Secure New European Patent
October 26, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
October 26, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Granted Two US Patents Protecting Exclusive Deuterated DMT Program
October 25, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
October 25, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
October 23, 2023
Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement.
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
October 23, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
October 23, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
October 22, 2023
Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts
Via
Benzinga
Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business
October 20, 2023
Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc.
Via
Benzinga
Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement
October 18, 2023
Short-acting psychedelics biotech Small Pharma Inc.
Via
Benzinga
Small Pharma Obtains Final Order Approving Arrangement
October 17, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
October 16, 2023
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution
Via
Benzinga
Exposures
Product Safety
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates
October 13, 2023
Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc.
Via
Benzinga
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Reports on Voting Results from Annual Shareholder Meeting
October 13, 2023
Via
Investor Brand Network
Cybin Announces Results of Annual and Special Meeting of Shareholders
October 12, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
October 06, 2023
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares
Via
Benzinga
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Abstract Selected for Presentation at Sixth Annual Neuropsychiatric Drug Development Summit
October 06, 2023
Via
Investor Brand Network
Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit
October 06, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 04, 2023
Via
Investor Brand Network
Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit
October 04, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Completes Dosing In Phase 2 Study Of CYB003 For Major Depressive Disorder Treatment
October 03, 2023
Cybin Inc. (NYSE: CYBN), a clinical-stage biotech company developing novel psychedelic-based mental health treatments, has completed dosing of the final participant cohort in the
Via
Benzinga
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares
October 03, 2023
NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management...
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Wraps Up Phase 2 Study Dosing for Final Cohort
October 03, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.